The popularity of copyright’s blockbuster initially sparked a boom for pharma, but recent shifts present a murky scenario for shareholders. Off-patent competitors are eroding profits, and persistent patent challenges https://denisifwq666659.verybigblog.com/39998719/sildenafil-and-big-pharma-a-risky-bet